This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Altundag, K. Articles by Ibrahim, N. K. Search for Related Content PubMed PubMed Citation Articles by Altundag, K. Articles by Ibrahim, N. K.

Breast Cancer

Aromatase Inhibitors in Breast Cancer: An Overview

^a Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA; ^b Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Key Words. Breast cancer • Hormone receptor-positive • Aromatase inhibitor

Correspondence: Nuhad K. Ibrahim, M.D., Department of Breast Medical Oncology, Unit 424, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030-4009, USA. Telephone: 713-792-2817; Fax: 713-794-4385; e-mail: nibrahim{at}mdanderson.org

We examined published reports on the use of aromatase inhibitors in postmenopausal patients with hormone receptor-positive breast cancer. Our data were obtained through a MEDLINE search of literature published in English. Current data indicate that aromatase inhibitors are equivalent or superior to tamoxifen as first-line therapy for metastatic breast cancer and as neoadjuvant treatment for primary breast cancer. In addition, randomized studies have shown that aromatase inhibitors can be administered instead of tamoxifen as a single agent for 5 years or sequentially with tamoxifen for 5 or 10 years. These choices should be discussed with the patient, considering the estimated risk for recurrence and other associated comorbid conditions such as osteoporosis and thromboembolism.

This article has been cited by other articles:

				S. Catalano, I. Barone, C. Giordano, P. Rizza, H. Qi, G. Gu, R. Malivindi, D. Bonofiglio, and S. Ando Rapid Estradiol/ER{alpha} Signaling Enhances Aromatase Enzymatic Activity in Breast Cancer Cells Mol. Endocrinol., October 1, 2009; 23(10): 1634 - 1645. [Abstract] [Full Text] [PDF]

				G. E de Blaquiere, F. E B May, and B. R Westley Increased expression of both insulin receptor substrates 1 and 2 confers increased sensitivity to IGF-1 stimulated cell migration Endocr. Relat. Cancer, June 1, 2009; 16(2): 635 - 647. [Abstract] [Full Text] [PDF]

				X. Wang, S. Masri, S. Phung, and S. Chen The Role of Amphiregulin in Exemestane-Resistant Breast Cancer Cells: Evidence of an Autocrine Loop Cancer Res., April 1, 2008; 68(7): 2259 - 2265. [Abstract] [Full Text] [PDF]

				R. Ponzone, P. Mininanni, E. Cassina, F. Pastorino, and P. Sismondi Aromatase inhibitors for breast cancer: different structures, same effects? Endocr. Relat. Cancer, March 1, 2008; 15(1): 27 - 36. [Abstract] [Full Text] [PDF]

				C. L. Rock, S. W. Flatt, G. A. Laughlin, E. B. Gold, C. A. Thomson, L. Natarajan, L. A. Jones, B. J. Caan, M. L. Stefanick, R. A. Hajek, et al. Reproductive Steroid Hormones and Recurrence-Free Survival in Women with a History of Breast Cancer Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 614 - 620. [Abstract] [Full Text] [PDF]